Graham Capital Management, L.P. Bicycle Therapeutics PLC Transaction History
Graham Capital Management, L.P.
- $5.17 Billion
- Q2 2025
A detailed history of Graham Capital Management, L.P. transactions in Bicycle Therapeutics PLC stock. As of the latest transaction made, Graham Capital Management, L.P. holds 13,102 shares of BCYC stock, worth $109,663. This represents 0.0% of its overall portfolio holdings.
Number of Shares
13,102Holding current value
$109,663% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding BCYC
# of Institutions
118Shares Held
42.2MCall Options Held
111KPut Options Held
16.6K-
Baker Bros. Advisors LP New York, NY10.9MShares$91.1 Million0.77% of portfolio
-
Fcpm Iii Services B.V. Naarden, P73.45MShares$28.9 Million6.5% of portfolio
-
Armistice Capital, LLC New York, NY2.8MShares$23.4 Million0.34% of portfolio
-
Westfield Capital Management CO LP Boston, MA2.66MShares$22.2 Million0.12% of portfolio
-
Siren, L.L.C. New York, NY2.01MShares$16.8 Million0.72% of portfolio
About BICYCLE THERAPEUTICS plc
- Ticker BCYC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 29,676,100
- Market Cap $248M
- Description
- Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The co...